Advertisement

A Multi-Center Real-World Experience of IMpower150 in Oncogene Driven Tumors and CNS Metastases

Published:August 06, 2022DOI:https://doi.org/10.1016/j.cllc.2022.07.016

      Abstract

      Background

      There are limited real world data on the IMpower150 regimen in oncogene driven tumors and central nervous system metastases; this study aims to address this gap.

      Materials and Methods

      Retrospective analysis of patients with advanced non-small cell lung cancer treated with the IMpower150 regimen across 12 Australian sites between July 2018 and April 2021. Clinicopathologic and treatment parameters were correlated with efficacy and toxicity.

      Results

      A total of 106 patients identified with median follow up of 8 months (range 0-72). Median age was 61 years (range 33-83), 34% Asian and 58% never-smokers. An oncogene was reported in 94 (89%) patients, EGFR in 72 (68%). At treatment commencement, 50 (47%) patients had brain metastases, 21 (20%) leptomeningeal disease (LMD) and 47 (44%) liver metastases. 27% were treatment-naïve and pemetrexed was substituted for paclitaxel in 44 (42%). The overall response rate was 51% for all patients; 52% in patients with EGFR mutations. Patients with untreated brain metastases prior to commencing IMpower150 had a similar intracranial response as those with treated brain metastases (55% vs. 53%). The median time to treatment failure and overall survival from commencement of IMpower150 was 5.7 and 11.4 months respectively for the entire cohort and 5.2 and 10.5 months in those with an EGFR sensitizing mutation. Overall survival in patients with liver, brain metastases and LMD was 11.0, 11.4, and 7.1 months respectively. No new safety signals seen.

      Conclusion

      In this largely oncogene positive, pre-treated population the IMpower150 regimen demonstrated clinically-meaningful responses, including in patients with CNS disease.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinical Lung Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Borghaei H.
        • Langer C.J.
        • Gadgeel S.
        • et al.
        24-month overall survival from KEYNOTE-021 cohort G: Pemetrexed and carboplatin with or without Pembrolizumab as first-line therapy for advanced nonsquamous non–small cell lung Cancer.
        Journal of Thoracic Oncology. 2019; 14: 124-129
        • Garon E.B.
        • Hellmann M.D.
        • Rizvi N.A.
        • et al.
        Five-year overall survival for patients with advanced non‒small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study.
        Journal of Clinical Oncology. 2019; 37: 2518
        • Gettinger S.
        • Horn L.
        • Jackman D.
        • et al.
        Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study.
        Journal of Clinical Oncology. 2018; 36: 1675-1684
        • Brahmer J.
        • Reckamp K.L.
        • Baas P.
        • et al.
        Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer.
        New England Journal of Medicine. 2015; 373: 123-135
        • Reck M.
        • Rodriguez-Abreu D.
        • Robinson A.
        • et al.
        Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.
        Journal of Clinical Oncology. 2019; 37: 537-546
        • Socinski M.A.
        • Jotte R.M.
        • Cappuzzo F.
        • et al.
        Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC.
        New England Journal of Medicine. 2018; 378: 2288-2301
        • Manegold C.
        • Dingemans A.M.C.
        • Gray J.E.
        • et al.
        The potential of combined immunotherapy and antiangiogenesis for the synergistic treatment of advanced NSCLC.
        Journal of Thoracic Oncology. 2017; 12: 194-207
        • Gabrilovich D.I.
        • Chen H.L.
        • Girgis K.R.
        • et al.
        Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells.
        Nature medicine. 1996; 2: 1096-1103
        • Oyama T.
        • Ran S.
        • Ishida T.
        • et al.
        Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-κB activation in hemopoietic progenitor cells.
        The Journal of Immunology. 1998; 160: 1224-1232
        • Wallin J.J.
        • Bendell J.C.
        • Funke R.
        • et al.
        Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.
        Nature communications. 2016; 7: 1-8
        • Reck M.
        • Mok T.S.K.
        • Nishio M.
        • et al.
        Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.
        The Lancet Respiratory Medicine. 2019; 7: 387-401
        • Nogami N.
        • Barlesi F.
        • Socinski M.A.
        • et al.
        IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.
        Journal of Thoracic Oncology. 2021; 17: 309-323
        • Lam T.
        • Tsang K.C.
        • Choi H.C.
        • et al.
        Combination atezolizumab, bevacizumab, pemetrexed and carboplatin for metastatic EGFR mutated NSCLC after TKI failure.
        Lung Cancer. 2021; 159: 18-26
        • Reck M.
        • Wehler T.
        • Orlandi F.
        • et al.
        Safety and Patient-Reported Outcomes of Atezolizumab Plus Chemotherapy With or Without Bevacizumab Versus Bevacizumab Plus Chemotherapy in Non–Small-Cell Lung Cancer.
        Journal of Clinical Oncology. 2020; 38: 2530
        • Liao B.-C.
        • Lee J.H.
        • Lin C.C.
        • et al.
        Epidermal growth factor receptor tyrosine kinase inhibitors for non–small-cell lung cancer patients with leptomeningeal carcinomatosis.
        Journal of Thoracic Oncology. 2015; 10: 1754-1761
        • Umemura S.
        • Tsubouchi K.
        • Yoshioka H.
        • et al.
        Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
        Lung Cancer. 2012; 77: 134-139
        • Yang J.C.
        • Kim S.W.
        • Kim D.W.
        • et al.
        Osimertinib in patients with epidermal growth factor,BLOOM study.
        Journal of Clinical Oncology. 2020; 38: 538
        • Ahn M.-J.
        • Chiu C.H.
        • Cheng Y.
        • et al.
        Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis.
        Journal of Thoracic Oncology. 2020; 15: 637-648
        • Park S.
        • Lee M.H.
        • Seong M.
        • et al.
        A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
        Annals of Oncology. 2020; 31: 1397-1404
        • Gaye E.
        • Geier M.
        • Bore P.
        • et al.
        Intra-cranial efficacy of brigatinib in an ALK-positive non-small cell lung cancer patient presenting leptomeningeal carcinomatosis.
        Lung Cancer. 2019; 133: 1-3
        • Pacheco J.M.
        • Camidge D.R.
        Searching for a chemoimmunotherapy signal in patients with non-small-cell lung cancer and EGFR mutations. The Lancet.
        Respiratory medicine. 2019; 7: 366-367
        • Lu S.
        • Wu L.
        • Jian H.
        • et al.
        VP9-2021: ORIENT-31: Phase III study of sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated nonsquamous NSCLC who progressed after EGFR-TKI therapy.
        Annals of Oncology. 2022; 33: 112-113
        • Riely G.
        • Hui R.
        • Carbone D.
        • et al.
        P1. 01-81 phase 3 study of pemetrexed-platinum with or without pembrolizumab for TKI-resistant/EGFR-mutated advanced NSCLC: KEYNOTE-789.
        Journal of Thoracic Oncology. 2018; 13: S494
        • Nakagawa K.
        • Yang J.C.H.
        • Park K.
        • et al.
        481TiP Checkmate 722: a phase 3 trial of nivolumab with chemotherapy or ipilimumab vs chemotherapy in epidermal growth factor receptor (EGFR)-mutation, T790M-negative stage IV or recurrent non-small cell lung cancer (NSCLC) after EGFR tyrosine kinase inhibitor (TKI) therapy.
        Annals of Oncology. 2016; 27: ix154-ix155
        • To K.K.
        • Fong W.
        • Cho W.C.
        Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
        Frontiers in Oncology. 2021; 11 (635007)